UK Standards for Microbiology Investigations

Investigation of orthopaedic implant associated infections
Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

We also acknowledge Dr Bridget Atkins of the Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford and the UK Standards for Microbiology Investigation Working Group for Clinical Bacteriology for their considerable specialist input.

For further information please contact us at:
Standards Unit
Microbiology Services
Public Health England
61 Colindale Avenue
London NW9 5EQ
E-mail: standards@phe.gov.uk
Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories

PHE publications gateway number: 2015712

UK Standards for Microbiology Investigations are produced in association with:
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGMENTS</td>
<td>2</td>
</tr>
<tr>
<td>AMENDMENT TABLE</td>
<td>4</td>
</tr>
<tr>
<td>UK SMI: SCOPE AND PURPOSE</td>
<td>6</td>
</tr>
<tr>
<td>SCOPE OF DOCUMENT</td>
<td>9</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>9</td>
</tr>
<tr>
<td>TECHNICAL INFORMATION/LIMITATIONS</td>
<td>15</td>
</tr>
<tr>
<td>1 SAFETY CONSIDERATIONS</td>
<td>17</td>
</tr>
<tr>
<td>2 SPECIMEN COLLECTION</td>
<td>17</td>
</tr>
<tr>
<td>3 SPECIMEN TRANSPORT AND STORAGE</td>
<td>18</td>
</tr>
<tr>
<td>4 SPECIMEN PROCESSING/PROCEDURE</td>
<td>18</td>
</tr>
<tr>
<td>5 REPORTING PROCEDURE</td>
<td>24</td>
</tr>
<tr>
<td>6 NOTIFICATION TO PHE, OR EQUIVALENT IN THE DEVOLVED ADMINISTRATIONS</td>
<td>26</td>
</tr>
<tr>
<td>APPENDIX: INVESTIGATION OF ORTHOPAEDIC IMPLANT ASSOCIATED INFECTIONS BY CULTURE</td>
<td>27</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>29</td>
</tr>
</tbody>
</table>

---

NICE has accredited the process used by Public Health England to produce Standards for Microbiology Investigations. Accreditation is valid for 5 years from July 2011. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).
Investigation of orthopaedic implant associated infections

Amendment table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from standards@phe.gov.uk.

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

<table>
<thead>
<tr>
<th>Amendment no/date.</th>
<th>4/23.02.16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>1.3</td>
</tr>
<tr>
<td>Insert issue no.</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section(s) involved</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole document.</td>
<td>Title changed to ‘Investigation of orthopaedic implant associated infections’. References updated throughout.</td>
</tr>
<tr>
<td>Scope.</td>
<td>Fixation devices added to types of specimen. Scope updated to reflect new title and use of molecular techniques.</td>
</tr>
<tr>
<td>Introduction.</td>
<td>Re-structured and streamlined for clarity. Information regarding sample types, sampling, sample processing and molecular methods inserted and updated (previously in Technical Information/Limitations). Synovial white cell count cut offs for acute and chronic prosthetic joint infection included. Section on rapid techniques expanded to include MALDI-TOF MS. Information on sonication included. Gram staining in elective revision cases should not be considered for diagnosing infection. Recommends up to 5 days culture using either cooked meat broth or continuous monitoring blood culture system method, extended to 14 days in some cases.</td>
</tr>
<tr>
<td>Technical information/limitations.</td>
<td>Information included on sonication, small colony variants, contamination and effect of antibiotic use.</td>
</tr>
<tr>
<td>Safety considerations.</td>
<td>Avoid sharps where possible. Needless syringes are available for use with blood culture bottles. Ideally analysis should be carried out in a Class II...</td>
</tr>
<tr>
<td>Specimen collection.</td>
<td>If possible stop antibiotics 2 weeks prior to surgery. Swabs are discouraged. In theatres multiple (3 to 5) samples should be taken.</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Specimen transport and storage.</td>
<td>IDSA recommend samples are processed within 2 hrs.</td>
</tr>
</tbody>
</table>
| Specimen processing/procedure. | Ideally analysis should be carried out in a Class II cabinet. Primary plates may not be required in some situations. Enrichment broth/blood culture broth should be incubated for 5 days (extended to 14 days in certain situations). Method for total white and differential leucocyte counts included. Culture media, conditions and organisms table updated:  
- Standard media  
  - FAA, read at 3 and 5 day.  
  - Inclusion of continuous monitoring blood culture system.  
  - Broth incubation 5 days, extended to 14 days in certain situations.  
- Supplementary media  
  - Sabouraud agar, incubate for 14 days.  
- Addition of molecular techniques (NAAT). Identification – isolates should be kept for at least 2 weeks. Antimicrobial susceptibility testing updated to include extensive antibiograms. |
| Reporting procedure. | Updated to include total white and differential cell counts. Culture reporting updated in line with new template. Molecular reporting added. |
| Appendix. | Updated in line with section 4.5.3 Culture media, conditions and organisms. |
UK SMI#: scope and purpose

Users of SMIs
Primarily, SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK. SMIs also provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests. The documents also provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

Background to SMIs
SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages. Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

Equal partnership working
SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies. The list of participating societies may be found at https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories. Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and working groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process. SMIs are developed, reviewed and updated through a wide consultation process.

Quality assurance
NICE has accredited the process used by the SMI working groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008. SMIs represent a good standard of practice to which all clinical and public health microbiology

---

Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.
Investigation of orthopaedic implant associated infections

Laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development. The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

**Patient and public involvement**

The SMI working groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

**Information governance and equality**

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions. The development of SMIs is subject to PHE Equality objectives [https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity](https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity).

The SMI working groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

**Legal statement**

While every care has been taken in the preparation of SMIs, PHE and the partner organisations, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made by an end user to an SMI for local use, it must be made clear where in the document the alterations have been made and by whom such alterations have been made and also acknowledged that PHE and the partner organisations shall bear no liability for such alterations. For the further avoidance of doubt, as SMIs have been developed for application within the UK, any application outside the UK shall be at the user’s risk.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the date of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

**Suggested citation for this document**

Scope of document

Type of specimen
Prosthetic joint aspirate, peri-prosthetic biopsy, intra-operative specimens (debridement and retention or revision arthroplasty), prostheses, fixation devices

This SMI describes the microbiological investigation of orthopaedic implant associated infection samples and includes information on molecular techniques.

For information regarding bone and tissue samples associated with osteomyelitis refer to B 42 – Investigation of bone and soft tissue associated with osteomyelitis.

This SMI should be used in conjunction with other SMIs.

Introduction

Since the earliest hip replacements, pioneered in the UK by Sir John Charnley in the early 1960s, joint replacement (arthroplasty) has become a common procedure. It is done most commonly for osteoarthritis and inflammatory arthropathies such as rheumatoid arthritis. For hip fractures, a hemiarthroplasty is one of the surgical treatment options. Hip and knee replacements are more common than replacements of shoulder, elbow, ankle and interphalangeal joints. Bilateral replacements for osteoarthritis are common in weight bearing joints and multiple joint replacements are common in inflammatory arthritis. Revision surgery is done for joint failure (usually loosening or recurrent dislocation) and the majority are ‘aseptic’. Around 15% of revisions are due to ‘septic’ loosening.

Risk factors for infection

Infection rates are now much lower than when joint replacement was first introduced. There is however still a risk associated with each procedure. This is around 1-2% for elective hip and knee replacements and higher for emergency trauma operations eg hemiarthroplasties. The risk of infection in a joint replacement is increased by patient factors, including; the early development of a surgical site infection not apparently involving the prosthesis, a National Healthcare Safety Network (NHSN) Score of one or two, the presence of malignancy and previous joint arthroplasty. The NHSN score encompasses both surgical and patient factors such as the duration of surgery, degree of wound contamination and patient’s preoperative health. Other co-morbidities such as immunosuppression, diabetes, renal failure, heart or lung disease, smoking and obesity also increase the risk of infection after surgery, as does prolonged post-operative wound drainage and haematoma formation.

Surveillance of surgical site infections may be used as a means to prevent such infections which are associated with considerable morbidity and extended hospital stay.

Pathogenesis and microbiology

Organisms may be introduced into the joint during primary implantation surgery, via a haematogenous (bloodstream) route or from post-operative contamination of the wound. These may cause acute or chronic infections. Fewer organisms are required to establish infection when there is a foreign body in situ than otherwise. The most
common organism to cause acute infections is *Staphylococcus aureus* (meticillin sensitive or resistant) and in chronic infections either *S. aureus* or coagulase negative staphylococci. It is estimated that up to 30% of *S. aureus* bacteraemias may be associated with septic arthritis in those with pre-existing prosthetic joints\(^1\). Many other organisms can be acquired by either direct inoculation or the haematogenous route including other skin flora, streptococci, coliforms, enterococci and rarely anaerobes, mycobacteria or fungi\(^5,13,14\).

Once infection is established around a prosthetic joint, organisms can form a “biofilm”\(^1\). Organisms secrete extracellular substances to produce a complex and sometimes highly organised glycolcalyx structure within which they are embedded. In these microbial communities, which may be polymicrobial, some organisms are dividing slowly if at all, and others may even be in a state akin to dormancy. In the microbiological diagnosis of infection, this biofilm may have to be disrupted in order to culture organisms\(^1\). The “persisters” within the biofilm are very difficult to kill so that infection may not be eradicated without removal of the prosthesis. If it is to be retained, antibiotics with activity against organisms which form biofilms should be used, but standard antimicrobial sensitivities may not predict the required antimicrobial activity\(^1\). In vitro models testing activity of antimicrobials against organisms within a biofilm are not at present feasible in routine laboratories.

**Clinical presentation**

Prosthetic joint infections can present acutely, with a hot, swollen painful joint. The patient is often febrile and can be clinically septic. Inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are usually raised\(^1\). This presentation needs to be differentiated from acute inflammatory arthritides such as rheumatoid arthritis, gout, pseudogout and also from an acute haematoma (blood) in the joint. Alternatively, prosthetic joint infections can present chronically. The joint may simply be painful and stiff. There may be evidence for loosening of the prosthesis on X-ray. Inflammatory markers may be slightly raised, but this is not specific\(^1\). These presentations are often difficult to differentiate from those of mechanical pain or aseptic loosening\(^1\). The presence of a discharging sinus however, indicates the presence of a deep prosthetic joint infection.

**Diagnosis**

In the acute presentation of prosthetic joint infection, in addition to a full clinical assessment of the patient, blood cultures should be taken and a joint aspirate performed. An ultrasound may aid this and will clarify whether there is fluid in the joint itself. Synovial fluid may be visibly purulent or merely turbid. Plain X-rays are performed to look for early loosening, fracture or other pathology. Plain X-rays may show loosening, but do not differentiate septic from aseptic loosening. In the chronically infected prosthetic joint, the diagnosis is much more difficult. A past history of early post-operative wound infection increases the likelihood of deep infection. If changes are rapidly progressive over time, infection is more likely. Nuclear radiology may have a role in diagnosis but scans can be non-specific or technically difficult to perform. Magnetic Resonance Imaging (MRI) and computerised tomography (CT) scans are rarely helpful. Inflammatory markers may only be slightly raised and are not specific or sensitive. Sinus cultures are not helpful as organisms cultured do not predict those causing deep infection\(^1\). A joint aspirate for cell count, culture and histology, or periprosthetic joint biopsy for microbiology and histology (using
ultrasound or other dynamic imaging), are the most specific tests for infection. As organisms may be in a ‘sessile’ biofilm form (rather than ‘planktonic’ and loose in the joint fluid) the sensitivity of a joint aspirate can be poor.

**Sample types**

**Percutaneous joint aspiration**

This is an important diagnostic sample for testing in both acute and chronic prosthetic joint infections. It is performed aseptically, ideally in radiology or in theatres. In acute infections, a Gram stain is useful although a negative result should not rule out the possibility of infection. In chronic infections the sensitivity of a Gram stain is <10%.\(^\text{20,21}\)

A semi-quantitative white cell count on the synovial fluid is useful for differentiating inflammatory from non-inflammatory arthritides; however it is less useful at differentiating infection from inflammation.\(^\text{2}\) A total synovial cell count may be helpful in certain clinical situations.\(^\text{22-24}\) Cut off values for synovial fluid leukocyte count and differential cell counts for the diagnosis of prosthetic joint infection have been determined in several studies.\(^\text{25,26}\) Leukocyte cut offs ranged from 1100 cells/µL to over 4000 cells/µL.\(^\text{24,27-30}\) Leukocyte differentials ranged from 64% to ≥80% neutrophils.\(^\text{24,27-30}\) These cut off values are lower than those in cases of septic arthritis.\(^\text{27,28}\) Specificity and sensitivity varied ranging from 82 to 98% and 84 to 97% respectively.\(^\text{24,27-30}\) In patients with underlying inflammatory disease, counts may be high even in the absence of infection. When appropriate, synovial fluid should also be examined for crystals. A synovial biopsy may also be considered.

The cut offs for acute prosthetic joint infection occurring within six weeks of surgery, as agreed (strong consensus) at the proceedings of the international consensus meeting on periprosthetic joint infections, are as follows:\(^\text{26}\):

- synovial white blood cell count (WBC) >10,000 cells/µL
- synovial neutrophil percentage (PMN%) >90%

The approximate cut off for chronic prosthetic joint infection, applicable to tests taken more than six weeks after the most recent surgery, are as follows:\(^\text{26}\):

- synovial white blood count (WBC) >3,000 cells/µL
- synovial neutrophil percentage (PMN%) >80%

Broth enrichment cultures are important as the patient may have already received antibiotics and in chronic cases the number of free (planktonic) organisms may be very low. In the presence of a joint prosthesis, any organism cultured may be relevant and should be identified, have sensitivity testing performed and be reported. Many chronic infections are due to “skin flora”. For this reason differentiating infection from contamination in a sample obtained as an aspirate is difficult. In addition the sensitivity of an aspirate in chronic infection may be poor. A peri-prosthetic tissue biopsy which can include histology could be considered.

**Percutaneous biopsy**

A peri-prosthetic biopsy can be obtained under ultrasound or other dynamic imaging, such as fluoroscopy. If the joint is loose, ideally this should be obtained from the bone cement interface or bone prosthesis interface. It has the advantage over needle
aspiration alone, that histology, looking for neutrophils, can also be carried out if multiple biopsies can be performed.

**Intra-operative biopsy**

Intra-operative biopsies may be performed in the chronically infected joint either solely as a diagnostic test, as part of a debridement and retention procedure, or when a joint is being revised. Joint revision is a common procedure and usually done for aseptic loosening. However, because infection can be occult, it is advisable to take multiple samples for microbiology and histology in all cases. In some cases, where available, this can be combined with a frozen section to aid surgical decision making.

**Explanted prostheses**

Explanted prostheses can be sent for microbiological investigation. They are often difficult to handle unless especially large pots are used leading to a potentially greater risk of contamination. Some laboratories sonicate the prostheses and culture the sonicate fluid. This can be done in addition to multiple samples but not to replace them.

Sonication, when used as an addition to conventional culture has been shown to improve the sensitivity of prosthetic joint infection microbiological diagnosis. It uses ultrasound to disrupt the bacterial biofilm on the prosthetic material. The improvement in sensitivity is most markedly seen in patients on antibiotics within 14 days prior to surgery.

**Sampling**

Samples of fluid, pus, synovium, granulation tissue, membrane (the tissue that forms at the bone-cement or bone-prosthesis interface) and any abnormal areas should be taken, in cases where the joint is being removed. Each specimen should be taken with a separate set of instruments, and should be placed into a separate specimen container. Pre-sterilised packs can be produced for this purpose. At this stage a frozen section may also be performed if available and required to decide between one and two stage exchange.

In centres where sonication is available, the prosthesis, or its components thereof, can be sent to the laboratory in a sterile watertight container.

**Sample processing**

Samples can be transferred to the laboratory using routine timescales (ie within hours rather than minutes). There are no published comparisons or validations of various tissue processing methods in the orthopaedic setting. The method of shaking with glass beads is relatively simple and carries a low risk of contamination which has been shown experimentally to be superior to shaking in broth alone in the recovery of Bacillus spores from polymer surfaces. Results of a study suggest that the use of glass beads in the microbiological examination of intra-operative periprosthetic samples may indeed be a useful addition to conventional culture leading to increased microbiological diagnosis rates with relatively low contamination rates.

Sonication of removed components has been examined as a means of disrupting bacterial biofilm in vascular and orthopaedic prostheses. A considerable number of studies have now been performed comparing sonication of the prosthesis in a sterile
pot to conventional cultures\textsuperscript{18,41-45}. Several centres have now adopted this as routine practice\textsuperscript{1,46-48}.

**Microscopy and culture\textsuperscript{49}**

Gram staining in elective revision cases should not be considered for diagnosing infection as it has extremely poor sensitivity\textsuperscript{20,21,26,50,51}.

Gram staining can however be used in acute infection to distinguish between aggregates of ultrasound-dislodged biofilm bacteria from other debris and contaminating bacteria\textsuperscript{21}. These can appear as single cells or very small groups of cells. A negative Gram stain does not however rule out infection. False positive Gram stains associated with periprosthetic infections are rare, but may have severe consequences if used as the basis for treatment\textsuperscript{20}. One study investigating false positive intraoperative Gram stains in diagnosing periprosthetic infection reported a sensitivity and specificity of 9\% and 99\% respectively\textsuperscript{20}. Another study concluded that Gram stains have a limited application, and reported a sensitivity and specificity of 7\% and 92\% respectively\textsuperscript{52}.

Culture methods should include an enrichment broth. Cooked meat broth and continuous monitoring blood culture systems (CMBCS) have equivalent sensitivity, and are more sensitive than fastidious anaerobic agar plates in orthopaedic device related infection\textsuperscript{38,53-55}.

**Automation\textsuperscript{55}**

Some laboratories with a significant number of orthopaedic device related samples have opted to use automation using CMBCS to reduce labour and early subculture of culture broths\textsuperscript{38,53}.

**Duration of culture**

Traditionally orthopaedic samples have been cultured for up to five days. More recently evidence suggested that incubation of up to 14 days may be necessary to isolate less virulent organisms such as propionibacteria and diphtheroids\textsuperscript{26,56-60}. The methods described omit any early subculture unless broths are cloudy. Visual inspection of broth media is not very accurate; many earlier positives may have been missed and time to detection may depend on how frequently cultures are examined\textsuperscript{41}. Some broth enrichment methods require incubation for 14 days, however in a protocol based on vortexing with sterile beads and enrichment in cooked meat broth with terminal subculture after 5 days, the sensitivity of the broth enrichment after 5 days was almost equivalent to the sensitivity obtained with two blood cultures (aerobic and anaerobic) despite the lower inoculum used for the broth. If a set of aerobic and anaerobic bottles are used for the enrichment, an analysis of receiver-operator characteristics (ROC) has demonstrated that there is no need for incubation times exceeding 5 days\textsuperscript{38,55}. Full automation using CMBCS bottles suggests that > 98\% of significant results have flagged within 3 days\textsuperscript{55}.

This SMI therefore recommends up to 5 days culture using either cooked meat broth or continuous monitoring blood culture system methods\textsuperscript{41,55,62}. However, in cases of suspected prosthetic joint infection, with low virulence organisms, or where preoperative cultures have failed to show growth and the clinical picture is consistent with prosthetic joint infection, culture may be extended to 14 days\textsuperscript{26,63,64}.
Interpretation of results
Defining organisms in separate samples as indistinguishable can be difficult. One or two differences in an extended antibiogram may not always indicate strains from different clonal origins. In addition, infection of prostheses with multiple strains can occur. It is important to perform sensitivity testing on all isolates from all samples as the extended antibiogram is a common and cheap way to identify strains as indistinguishable in multiple cultures and the presence of resistant strains will affect the outcome of therapy.

Organisms can be cultured from 60 - 70% of samples taken from prostheses deemed infected. As the organisms that cause chronic prosthetic joint infection are frequently the same as those that contaminate microbiological samples, interpretation of results is difficult when only one or two samples are taken. When five samples are taken, the false positive rate with two or three samples positive is <5% whereas false positive rates close to 30% are seen with a single positive sample. Growth of an indistinguishable organism from two or more samples is 71% sensitive and 97% specific. Recovery of an indistinguishable organism from three samples is 66% sensitive and 99.6% specific. Obtaining organisms from a single tissue sample therefore poses significant challenges in interpretation. Even with careful sampling and prolonged cultures, there is still a significant culture negative rate, even when histology is positive. This may be due to sampling error (the distribution of organisms can be patchy), very small numbers of organisms that do not thrive in laboratory culture conditions, an inability to disrupt organisms from the biofilm, unculturable organisms or false positive histology results. Immunofluorescent and molecular studies suggest that, in some cases, there may be organisms present even when conventional cultures are negative.

Rapid techniques
Serology
Serological techniques used for diagnosis of prosthetic joint infection have been studied in the research setting but have not yet been found to be of practical clinical benefit. The problem tends to be with specificity.

Molecular methods
Nucleic acid amplification techniques (NAAT)
NAAT - Nucleic acid amplification techniques (eg PCR) for the identification of bacteria, fungi, parasites and viruses from clinical samples have been shown to be highly specific and sensitive. PCR targets conserved genes of the genome, and enables the rapid identification of organisms including those that are slow to grow or are unculturable. Results are available within a short timeframe particularly if multiplex real-time PCR is used.

NAAT including PCR, 16s rRNA gene PCR and PCR-electrospray ionization (ESI)/MS have been developed as a means of rapid, sensitive identification of organisms associated with prosthetic joint infection. PCR has been shown to be more sensitive than convention culture for the isolation of some fastidious organisms for example Kingella kingae, and PCR–hybridization after sonication has been shown to improve diagnosis of implant related infections. There are however some issues with NAAT analysis. A lowered sensitivity may be observed due to the small volume of
samples processed, in some cases there may be interference with human DNA originating from the tissue samples, and antibiotic susceptibility information is not available\textsuperscript{17,75}.

Future developments may include the coupling of broad range PCR with next generation sequencing allowing analysis of the total microbiome associated with orthopaedic implant associated infections\textsuperscript{71}.

**MALDI-TOF mass spectrometry\textsuperscript{76,77}**

Recent developments in identification of bacteria, and fungi include the use of protein profiles obtained by Matrix assisted laser desorption ionisation – time of flight (MALDI-TOF) mass spectrometry\textsuperscript{76}. Mass peaks achieved by the test strains are compared to those of known reference strains. It is possible for an organism to be identified from an isolate within a short time frame and it is increasingly being used in laboratories to provide a robust identification system\textsuperscript{67}.

Limited data is available on the use of MALDI-TOF MS in orthopaedic implant associated infection diagnosis; however, one study has shown that MALDI-TOF MS may be useful diagnostic tool for identifying isolates from patients with orthopaedic implant associated infections, providing reliable species level identification which may be used to differentiate between contaminates and pathogens\textsuperscript{78}.

**Technical information/limitations**

**Limitations of UK SMIs**

The recommendations made in UK SMIs are based on evidence (eg sensitivity and specificity) where available, expert opinion and pragmatism, with consideration also being given to available resources. Laboratories should take account of local requirements and undertake additional investigations where appropriate. Prior to use, laboratories should ensure that all commercial and in-house tests have been validated and are fit for purpose.

**Specimen containers\textsuperscript{79-81}**

SMIs use the term “CE marked leak proof container” to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: “The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes”.

Sonication containers are available. See below.

**Sonication\textsuperscript{4,27,37}**

Gram positive bacteria have been found to be resistant to the effect of ultrasound; Gram negative organisms may be more susceptible\textsuperscript{48}. The effect of sonication on fungi and *Mycobacterium* species is unknown.

There may be the potential for contamination of sonication fluid during collection or specimen processing. Particular care needs to be taken during opening and closing
the container lid, to ensure that no contact is made with inner surface of the lid. Contamination is usually indicated by low counts of environmental bacteria.

**Small colony variants**

Where primary plates are used they should be examined under magnification as small colony variants of staphylococci may be isolated from deep samples. Such small colonies may only become evident on prolonged culture. Thymidine dependent auxotrophs usually do not grow on blood agar and have atypical colonial appearance resembling haemophili or streptococci on chocolate agar. The true prevalence and clinical relevance of small colony forms in prosthetic joint infection is unclear.

**Contamination**

Repetitive subculture from the enrichment broth during incubation may lead to contamination; the use of continuous monitoring blood culture bottles reduces this risk.

**Effect of antibiotic use**

In cases where a prosthetic joint is chronically painful, functioning poorly and/or loose, an elective revision will be performed. Patients should be off antibiotics for at least 2 weeks. One study comparing the culture of samples obtained by sonication of the prostheses and conventional periprosthetic-tissue culture has shown that sensitivity of both culture methods is reduced in patients receiving antimicrobial therapy within 14 days before surgery. The effect of a single dose of antibiotic on the sensitivity of microbiological culture is unknown and, where the suspicion of infection is low, timely administration of prophylactic antibiotics is paramount (ie in the 30-60 minutes prior to skin incision). The timing of prophylactic antibiotics is a risk-benefit decision.

Revision arthroplasty involves the removal of a prosthetic joint and debridement followed by re-implantation. Re-implantation may or may not occur during the same operation. In patients with a known chronically infected joint or one where evidence of infection (purulence) is found intra-operatively, the preferred option in many centres is to remove the joint and do a thorough debridement without immediate re-implantation. This is termed the ‘first stage’ of a two stage revision. In some centres in selected cases however, one-stage revision is performed even in the presence of infection.
1 Safety considerations

1.1 Specimen collection, transport and storage
Care should be taken to avoid accidental injury when using "sharps". The use of sharp objects should be avoided wherever possible. Sterile, needleless syringes and blood transfer devices are commercially available which may be used for the aseptic transfer of sample homogenate into blood culture bottles.

Use aseptic technique.

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

1.2 Specimen processing
Containment Level 2.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

Ideally, microbiological analysis should be carried out in a Class II cabinet, using aseptic technique, to reduce the risk of contamination of the sample and to protect the user.

Refer to current guidance on the safe handling of all organisms documented in this SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

2 Specimen collection

2.1 Type of specimens
Prosthetic joint aspirate, peri-prosthetic biopsy, intra-operative specimens (debridement and retention or revision surgery), prostheses, fixation devices

2.2 Optimal time and method of collection
For safety considerations refer to Section 1.1.

Collect specimens before antimicrobial therapy where possible.

If possible stop all antibiotics at 2 weeks prior to sampling and consider not giving routine surgical prophylaxis until after sampling.

Collect specimens into appropriate CE marked leak-proof containers and place in sealed plastic bags.

To enable timely clinical management, samples should be processed urgently.

Swabs are to be discouraged. However if sent, swabs for bacterial and fungal culture should be placed into appropriate transport medium and transport in sealed plastic bags.
2.3 Adequate quantity and appropriate number of specimens

For aspirates and radiologically guided biopsies, it is usually only possible to send one sample to microbiology. In theatres, multiple (three to five) samples should be taken using separate instruments for microbiology. An equivalent set of samples should be taken for histology.

Specimen size should approximate 1mL.

Small volumes of synovial fluid (<1mL) may impede the recovery of organisms.

Numbers and frequency of specimen collection are dependent on clinical condition of patient.

3 Specimen transport and storage

3.1 Optimal transport and storage conditions

For safety considerations refer to Section 1.1.

Specimens should be transported and processed as soon as possible.

The Infectious Diseases Society of America (IDSA) guidelines recommend that specimens should be transported at room temperature, and should be processed immediately, and within a maximum of 2hr.

If processing is delayed, refrigeration is preferable to storage at ambient temperature.

4 Specimen processing/procedure

4.1 Test selection

N/A

4.2 Appearance

N/A

4.3 Sample preparation

Non-repeatable samples should be prioritised.

For safety considerations refer to Section 1.2.

4.3.1 Pre-treatment

Soft tissue samples

The objective should be to minimise the manipulation on the number of times any container is opened and resulting exposure of the operative sample to contamination.

It may be possible in units with high workloads of this specimen type to arrange provision and use of CE Marked leak proof container with approximately 10 glass beads and 5mL Ringer’s or normal saline to the operating theatre. It is not uncommon, however, for microbiology and histology specimen pots to be confused leading to difficulties in processing samples. Transfer of biopsies in theatres may diminish the...
risk of contamination during laboratory processing. In such circumstances homogenisation could be performed in the original container.

Alternatively, samples may be sent to the laboratory in CE Marked leak-proof container in a sealed plastic bag with no glass beads. Glass beads and Ringer’s or saline can be added in the laboratory, maintaining asepsis diligently. Ideally processing of samples should take place in a Class II cabinet. Homogenisation with glass beads can be performed, for example, by shaking at 250 rpm for 10 minutes in a covered rack on an orbital shaker or, alternatively, vortexing for 15 seconds (40Hz) (alternative methods of homogenisation may also be used).

The diluent for the glass beads and tissue should be Ringer’s or saline. Sterile molecular grade water and new universal containers should be used if direct PCR assays are planned. The volume used in the latter case should not exceed 2mL to maintain assay sensitivity.

Optional
N/A

4.3.2 Specimen processing

If available, microbiological analysis should be carried out in a Class II cabinet, using aseptic technique, to reduce the risk of contamination of the sample and to protect the user.

Inoculate plates and broth after homogenisation of soft tissue samples and prosthesis, or directly from aspirate fluid. Inoculate each agar plate (if used) with a drop of the solution using a sterile pipette (see Q 5 - Inoculation of culture media for bacteriology). Primary plates may not be required in elective revisions, in high volume units and skilled multiple site sampling.

In addition, place some of the solution into an enrichment broth. If mycobacterial cultures are required this solution can then be used to inoculate mycobacterial cultures. This is best done 24hr after the primary plates have been examined once, to decide if decontamination of the sample is required. For information regarding incubation conditions and duration refer to B 40 - Investigation of specimens for Mycobacterium species.

Incubate the enrichment broth for 5 days (culture may be extended to 14 days in certain situations), examining daily for evidence of growth. Subculture if cloudy, but otherwise perform a terminal subculture at 5 days. As an alternative to enrichment broth, samples may be cultured in an automatic continuous monitoring blood culture system for 5 days (extended to 14 days in certain situations). Only subculture bottles which flag positive; a terminal subculture at 5 days is not required.

For the isolation of individual colonies, spread inoculum using a sterile loop.

If done, primary plates should be examined with under magnification for small-colony variants. Care should be taken to distinguish small tissue fragments on the plate from small colonies. Small colony variants are often thymidine-dependent, if the patient has received co-trimoxazole. Such isolates may not grow well on horse blood agar due to partial lysis and release of thymidine phosphokinase from the red cells. The heating process used to produce chocolate agar destroys thymidine phosphokinase.
Optional
Specimens collected into appropriate CE marked leak proof containers should be used for microscopy and may be used for molecular techniques. Specimens for molecular testing should be processed according to manufacturer’s instructions.

4.4 Microscopy (refer TP 39 – Staining procedures)

4.4.1 Standard
N/A

4.4.2 Supplementary

Gram stain (refer to TP 39 - Staining procedures)

This is an insensitive procedure and not recommended for the pre or intra-operative diagnosis of chronic prosthetic joint infection.

It may however have a role in acute prosthetic joint infection especially on a purulent aspirate or surgical pus. It is important to distinguish between aggregates of ultrasound-dislodged biofilm bacteria from other debris and contaminating bacteria. These can appear as odd single cells or very small groups of cells. A negative Gram stain does not rule out infection.

Total white cell and differential leucocyte count

Total white cell counts and differential leucocyte counts may be performed on joint aspirates.

Total white cell count

The presence of a clot will invalidate a cell count.

Perform a total cell count on the synovial fluid in a counting chamber.

Differential leucocyte count - Toluidine blue/Methylene blue stain (Wright stain)
(refer to TP 39 - Staining procedures)

Note: When a particle counter has been validated for use with cells in this context then it may be used\textsuperscript{106}.

Differentiating between polymorphonuclear leucocytes and mononuclear leucocytes may be performed in two ways:

- Counting chamber method: recommended for lower WBC counts.
  a) Non- or lightly-blood stained specimens
    - stain the fluid with 0.1% stain solution such as toluidine, methylene or Nile blue. This stains the leucocyte nuclei thus aiding differentiation of the cells
    - the dilution factor must be considered when calculating the final cell count
    - count and record the numbers of each leucocyte type
    - express the leucocyte count as number of cells per litre
b) Heavily bloodstained specimens

- dilute specimen with WBC diluting fluid and leave for 5 minutes before loading the counting chamber. This will lyse the red blood cells and stain the leucocyte nuclei for differentiation
- count and record the number of each leucocyte type: the dilution factor must be considered when calculating the final cell count
- express the leucocyte count as number of cells per litre

- **Stained method**

  Recommended for very high WBC counts where differentiation in the counting chamber is difficult

  - prepare a slide from the centrifuged deposit or cytospin preparations as for the Gram stain but allow to air dry
  - fix in alcohol and stain with a stain suitable for WBC morphology
  
  **Note:** Heat fixation distorts cellular morphology

  - count and record the number of each leucocyte type as a percentage of the total

### 4.5 Culture and investigation

Inoculate each agar plate with sample using a sterile pipette (**Q 5 - Inoculation of culture media for bacteriology**).

For the isolation of individual colonies, spread inoculum with a sterile loop.

#### 4.5.1 Culture media, conditions and organisms

<table>
<thead>
<tr>
<th>Clinical details/ conditions</th>
<th>Specimen</th>
<th>Standard media</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All clinical conditions</td>
<td>All specimens</td>
<td>Blood agar and Chocolate agar</td>
<td>35 - 37</td>
<td>40-48hr</td>
<td>Daily</td>
</tr>
<tr>
<td>(Primary plates may not be needed in elective revisions, in high volume units and skilled multiple site sampling)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAA</td>
<td>35 - 37</td>
<td>Anaerobic</td>
<td>5 d</td>
<td>3 d and 5 d</td>
<td>Anaerobes</td>
</tr>
</tbody>
</table>
### Table: Fastidious anaerobic, cooked meat broth or equivalent.

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Specimen</th>
<th>Supplimentary media</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fungal infection suspected</td>
<td>All specimens</td>
<td>Sabouraud agar (slopes)</td>
<td>28-30°C Air</td>
<td>14 d Daily</td>
<td>Yeast and mould</td>
</tr>
</tbody>
</table>

Optional molecular techniques

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Specimen</th>
<th>Molecular technique</th>
<th>Instructions</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All clinical conditions</td>
<td>Bone marrow</td>
<td>NAAT</td>
<td>Follow manufacturer’s instructions</td>
<td>Any organism</td>
</tr>
</tbody>
</table>

Always consider other organisms such as *Mycobacterium* species (B 40 - Investigation of specimens for *Mycobacterium* species), fungi and actinomycetes.

* Broths should be examined periodically (ideally daily) and subcultured if there is evidence suggestive of growth. Terminal subcultures should be performed at 5 days.

** Blood culture subcultures should be performed when the bottle flags positive. A terminal subculture at 5 days is not required\(^{41,55}\).

*** Incubation may be extended if clinically indicated. For example in cases of suspected prosthetic joint infection with low virulence organisms, or where preoperative cultures have failed to show growth, and the clinical picture is consistent with prosthetic joint infection, culture may be extended to up to 14 days.

### 4.6 Identification

Refer to individual SMIs for organism identification.
4.6.1 Minimum level of identification in the laboratory

<table>
<thead>
<tr>
<th>Organism</th>
<th>Identification Level</th>
<th>Identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actinomycetes</td>
<td>genus level</td>
<td>ID 15 – Identification of anaerobic Actinomyces species</td>
</tr>
<tr>
<td>Anaerobes</td>
<td>genus level</td>
<td>ID 14 – Identification of anaerobic cocci</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ID 8 – Identification of Clostridium species</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ID 25 – Identification of anaerobic gram negative rods</td>
</tr>
<tr>
<td>β-haemolytic streptococci</td>
<td>Lancefield group level or species level</td>
<td></td>
</tr>
<tr>
<td>Other streptococci</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>Enterococci</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>Enterobacteriaceae</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>Yeast and mould</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>Haemophilus species</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>Pseudomonads</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>S. aureus</td>
<td>species level</td>
<td></td>
</tr>
<tr>
<td>Staphylococci (not aureus)</td>
<td>to coagulase negative Staphylococci or species level (if multiple samples)</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium species</td>
<td>B 40 – Investigation of specimens for Mycobacterium species</td>
<td></td>
</tr>
</tbody>
</table>

Organisms may be further identified if this is clinically or epidemiologically indicated.

**Note:** No organism should be considered to be a contaminant until cultures on all samples are concluded. Identification to species level and/or an extended antibiogram is normally necessary to detect whether isolates from multiple samples are indistinguishable.

**Note:** Laboratories should save all samples and isolates for at least 2 weeks in case further work (unusual organisms, molecular studies or further sensitivities) is required.

4.7 Antimicrobial susceptibility testing

Extensive antibiograms (including rifampicin) on multiple isolates are required\(^ {23,41,55} \). It is important to include a wide range of antibiotics particularly for those patients who may require prolonged oral treatment with biofilm active drugs. These antibiotics are not usually included in the common first line antimicrobials tested in most laboratories. For Gram positive organisms these may include a teicoplanin MIC plus antibiotics such as rifampicin, tetracycline, quinolone, co-trimoxazole, fusidic acid and linezolid.

Refer to British Society for Antimicrobial Chemotherapy (BSAC) and/or EUCAST guidelines. Prudent use of antimicrobials according to local and national protocols is recommended.

4.8 Referral for outbreak investigations

N/A
4.9 Referral to reference laboratories

For information on the tests offered, turnaround times, transport procedure and the other requirements of the reference laboratory click here for user manuals and request forms.

Organisms with unusual or unexpected resistance, or associated with a laboratory or clinical problem, or anomaly that requires elucidation should be sent to the appropriate reference laboratory.

Contact appropriate devolved national reference laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

England and Wales

Scotland

Northern Ireland
http://www.publichealth.hscni.net/directorate-public-health/health-protection

5 Reporting procedure

5.1 Microscopy

5.1.1 Standard
N/A

5.1.2 Supplementary
Gram stain
Report on organisms detected.

Note: Not to be used for diagnosis of chronic prosthetic joint infection.

White cell count
Report numbers of WBCs x 10^6 per litre.

Differential count
Report mononuclear leucocytes as percentage of the total WBCs.
5.1.2.1 Thresholds for white blood cell count and neutrophil percentage

<table>
<thead>
<tr>
<th></th>
<th>Approximate cut off for acute PJI ≤ 6 week after most recent surgery</th>
<th>Approximate cut off for acute PJI &gt; 6 week after most recent surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synovial white blood cell count (WBC)</td>
<td>&gt;10,000 cells/µL</td>
<td>&gt;3,000 cells/µL</td>
</tr>
<tr>
<td>Synovial neutrophil percentage (PMN%)</td>
<td>&gt;90%</td>
<td>&gt;80%</td>
</tr>
</tbody>
</table>

5.1.3 Microscopy reporting time
All results should be issued to the requesting clinician as soon as they become available, unless specific alternative arrangements have been made with the requestors.
Urgent results should be telephoned or transmitted electronically in accordance with local policies.

5.2 Culture
Following results should be reported:
- all organisms
- absence of growth

Intra-operative samples interpretation: two or more samples with an indistinguishable organism is indicative of a prosthetic joint infection.

5.2.1 Culture reporting time
Interim or preliminary results should be issued on detection of potentially clinically significant isolates as soon as growth is detected, unless specific alternative arrangements have been made with the requestors.
Urgent results should be telephoned or transmitted electronically in accordance with local policies.
Final written or computer generated reports should follow preliminary and verbal reports as soon as possible.

Note: Due to extended incubation in certain situations, some final reports may not be available until >14 days.

Also, report results of supplementary investigations.
Supplementary investigations: B 40 - Investigation of specimens for *Mycobacterium* species.

5.3 Molecular
Report results as per manufacturer’s instructions:
- detected
- not detected
5.4 Antimicrobial susceptibility testing

Report susceptibilities as clinically indicated. Prudent use of antimicrobials according to local and national protocols is recommended.

6 Notification to PHE\textsuperscript{108,109}, or equivalent in the devolved administrations\textsuperscript{110-113}

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

Note: The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAIs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.

https://www.gov.uk/government/organisations/public-health-england/about/our-governance#health-protection-regulations-2010

Other arrangements exist in Scotland\textsuperscript{110,111}, Wales\textsuperscript{112} and Northern Ireland\textsuperscript{113}. 
Appendix: Investigation of orthopaedic implant associated infections by culture\(^a, b\)

**Specimen**

**Standard**
- Blood agar and Chocolate agar
  - Incubate at 35-37°C 5-10% CO\(_2\) 40-48hr Read daily

**Supplementary**
- Blood culture or fastidious anaerobic broth (or equivalent)\(^a,e\)
  - Incubate at 35-37°C up to 5 d

**Blood culture (CMBCS)**
- Incubate at 35-37°C 5-10% CO\(_2\) (or for cooked meat in air)
- Sub-culture if evidence of growth or at 5 d

**FA broth or equivalent**
- Incubate at 35-37°C up to 5 d
- Sub-culture bottles that flag positive

**Sabouraud agar**
- Blood culture (CMBCS)
  - Incubate at 28-30°C in air for 14 d Read daily
  - Sub-culture if evidence of growth or at 5 d

**Suspected fungal infection**
- If prosthesis undergoes open debridement/removal/excision

**Removed prosthesis or modular components**
- Consider sonication

**Quantification of bacterial growth. Cut off 50 CFU/mL. Identify and do extended antibiogram on all isolates above cut off**

**Any organism**
- Yeast Mould\(^f\)

**Data ids**
- Staphylococci ID 7
- Streptococci ID 4
- Enterococci ID 4
- Enterobacteriaceae ID 16
- Pseudomonads ID 17
- Fastidious Gram negative ID 17
- Yeasts and moulds

**Anaerobes**
- Incubate anaerobically for 48hr Read daily
- Any organism
  - Refer IDs\(^f\)

**Blood agar**
- Incubate in CO\(_2\) for 48hr Read daily

**Chocolate agar**
- Any organism
  - Refer IDs\(^f\)

**Yeast**
- Mould\(^f\)
Footnotes

a) Laboratories should save all samples and isolates for at least 2 weeks in case further work (unusual organisms, molecular studies or further susceptibilities) is required.

b) Microbiological tests may not be required for synovial biopsy specimens if proceeding straight to revision/removal.

c) Mycobacterial cultures if any clinical suspicion eg ethnic origin, plus previous unexplained culture negative samples, granulomas on histology, chest-X-ray findings, and previous history of TB (see B 40 – Investigation of specimens for *Mycobacterium species*).

d) As an alternative to enrichment broth, samples may be cultured in an automatic continuous monitoring blood culture system (CMBCS) for up to 5 days. Terminal subculture is not required.

e) In cases of suspected prosthetic joint infection, with low virulence organisms, or where preoperative cultures have failed to show growth and the clinical picture is consistent with prosthetic joint infection, culture may be extended to 14 days\(^2\).

f) Interpretation of intra-operative samples: Two or more samples with an indistinguishable organism are a positive microbiology result.
References


79. European Parliament. UK Standards for Microbiology Investigations (SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes". 1998.


Investigation of orthopaedic implant associated infections


